The mean visual logMAR visual acuity ± standard deviation was 0.718 ± 0.779 (Snellen visual acuity equivalent 20/104).
Accurate assessment of baseline visual acuity was a key criterion for recruitment into our study and for calculating the success of various methods of refraction in correcting vision.
Exclusion criteria included visual acuity of 20/40 or worse, congenital colour blindness, history of ophthalmological disease, advanced cataracts, and/or any chronic disease not associated with diabetes that could affect the visual system.
Retreatment with a single aflibercept injection was performed according to any of the following criteria: (1) visual acuity loss of at least five letters with OCT evidence of fluid in the macula; (2) persistent or recurrent intraretinal or subretinal fluid on OCT; (3) new subretinal hemorrhage from the CNV.
The observers were selected according to the following 4 criteria: (1) Visual acuity of each eye (with full spherical and cylindrical correction) at least 1.0decimal (= 6/6Snellen), (2) absence of strabismus, ascertained with the unilateral cover test, (3) absence of a prism in the spectacles, and (4) presence of random dot stereopsis (Lang Test 1).
An additional nine 5-year-olds were excluded from the dataset, with one child failing to pass the visual acuity screening, one failing to reach criterion (see Section 2.3.1), three not performing significantly above chance in the catch trials (see Section 2.6.2) and four obtaining motion coherence thresholds above 100%, indicating an inability to perform the task.
To compare the efficacy and safety of ranibizumab 0.5 mg, guided by visual acuity (VA) stabilization or disease activity criteria, versus verteporfin photodynamic therapy (vPDT) in patients with visual impairment due to myopic choroidal neovascularization (CNV).
Inclusion criteria were corrected visual acuity ≥ 0.8, intraocular pressure <22 mmHg.
Inclusion criteria were best visual acuity better than 0.7 logMAR units at Snellen optotype in the eye affected by neovascular AMD, intraocular pressure (IOP) less than 20 mmHg, without current or past topic hypotensive therapy, and ultrasonic pachymetry between 520 and 580 μm.
Routine examinations measure visual acuity, visual fields, and ocular pressure.
